Argent Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Argent Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-47,155	Closed	-$3.44M	–	194
2019 Q3	$3.44M	Hold	47,155	–	–	0.13%	75
2019 Q2	$3.88M	Buy	47,155 +6,520	+16%	+$464K	0.15%	74
2019 Q1	$2.87M	Buy	40,635 +10,150	+33%	+$597K	0.1%	87
2018 Q4	$1.37M	Sell	30,485 -15,275	-33%	-$801K	0.07%	110
2018 Q3	$2.59M	Buy	45,760 +9,825	+27%	+$601K	0.09%	102
2018 Q2	$2.4M	Buy	35,935 +17,790	+98%	+$1.11M	0.09%	110
2018 Q1	$1.06M	Buy	+18,145	New	+$1.15M	0.04%	135
2016 Q1	–	Sell	-20,700	Closed	-$934K	–	206
2015 Q4	$934K	Sell	20,700 -19,675	-49%	-$847K	0.04%	132
2015 Q3	$1.59M	Buy	40,375 +16,075	+66%	+$915K	0.08%	112
2015 Q2	$1.51M	Buy	+24,300	New	+$1.45M	0.07%	124

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Argent Capital Management's ANIP Position: Q4 2019 in Review

Argent Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2019, closing a stake of 47,155 shares — an estimated $3.44M sold.

Argent Capital Management first reported a position in ANIP in Q2 2015 and held it in 10 quarters. The position peaked at $3.88M in Q2 2019. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2019.

Argent Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Argent Capital Management sold 47,155 ANI Pharmaceuticals shares in Q4 2019, an estimated $3.44M.
Argent Capital Management first reported a position in ANI Pharmaceuticals in Q2 2015 and held it in 10 quarters.
Argent Capital Management's ANI Pharmaceuticals position peaked at $3.88M in Q2 2019.
170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2019.

Based on Argent Capital Management's 13F filing for Q4 2019, filed 10 Feb 2020.